Articles tagged with Drug Discovery
Insilico Medicine has identified 9 potential dual-purpose targets against aging and 14 major age-related diseases using Microsoft BioGPT. The proposed genes include CCR5 and PTH, which have not been previously correlated to the aging process.
Researchers identified potential therapeutic targets for Alzheimer's disease and other conditions using a new approach combining AI-driven target identification with protein phase separation analysis. The study provides insights into the role of protein phase separation in human disease and its potential as a therapeutic target.
Researchers at University of California - Riverside uncover COVID's Achilles heel - its dependence on key human proteins. By understanding how the virus interacts with human cells, a new class of antiviral medication may be developed to block replication and treatment.
Researchers at Mount Sinai identified the structure of a red blood cell transporter and how it interacts with drugs. They discovered novel compounds capable of blocking the transporter, potentially leading to new treatments for conditions like hemolytic anemias.
The August 2023 issue of SLAS Technology features original research articles on nanodiamonds, automated buffer exchange, and epidermal growth factor. A new scheduling method called SAGAS is proposed to optimize life science experiments in laboratory automation.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
A miniature human heart model, approximately half a grain of rice in size, has been developed to transform drug testing and cardiovascular research. This self-paced, multi-chambered model provides real-time measurements of essential parameters, enabling unprecedented insights into heart function and diseases.
Insilico Medicine's inClinico platform uses generative AI to predict Phase II to Phase III clinical trial success with an accuracy of 79%. The tool has been validated in various studies and can provide valuable insights for investors and biotech/pharma companies.
Researchers at Penn State have discovered a safe and efficient way to create cyclopropanes, key features in many drugs, using a previously undescribed chemical process. The new method uses visible light and common ingredients to transform alkenes into cyclopropanes with no carbene intermediate.
Researchers at Insilico Medicine discovered novel inhibitors for salt-inducible kinase 2 (SIK2), a potential target for anti-inflammation and anti-cancer therapy. The findings were published in the July 13 edition of Bioorganic & Medicinal Chemistry, demonstrating the power of Insilico's Pharma.AI platform.
Researchers at NYU College of Dentistry developed a gene therapy that regulates sodium ion channel activity to alleviate chronic pain. By targeting the specific region where CRMP2 binds to NaV1.7, they were able to reduce sodium influx and quiet down neurons, providing relief from pain in cell and animal studies.
The latest issue of SLAS Discovery features novel technologies and approaches to develop and characterize chemical and biological tools for human disease treatment. The journal reports on high-throughput screening-related research, including fluorescence polarization assay use and glycomimetics.
Researchers at Tokyo University of Science successfully synthesized tanzawaic acid B in large amounts, paving the way for new antibiotic development. The breakthrough method could lead to creation of various compounds for pharmaceuticals, including new antibiotic candidates.
The study evaluates recent research on artificial intelligence-generated molecular structures from the perspective of medicinal chemists, recommending guidelines for assessing novelty and validity. Insilico Medicine's recommendations aim to improve the process of generating and evaluating novel AI-generated drugs.
Scientists used Insilico Medicine's generative AI platform to identify actionable drug targets for cystinosis and validate them in preclinical models. The study found that hyperactive mTOR signaling drives kidney tubular cell dysfunction, making it a targetable pathway.
Researchers at the University of Zurich have used AI to uncover the underlying cellular mechanism behind kidney disease in cystinosis. They identified a causal association between mTORC1 protein regulation and the disease, highlighting a promising therapeutic target.
Using MRI instead of CT with CTA alone in patients presenting to the ED with dizziness was associated with greater critical neuroimaging results and more frequent echocardiography. Patients with dizziness undergoing MRI showed a lower frequency of 90-day ED readmissions compared to those discharged after CT with CTA alone.
A team from the University of Ottawa has developed a comprehensive screening platform and cellular interrogation tool to facilitate novel drug discovery targeting various human diseases. The 'Tango-Trio' platform can identify small molecule modulators for orphan GPCRs, which have significant untapped therapeutic potential.
A proof-of-concept study demonstrates the effectiveness of two supporting matrices in growing spheroids derived from patient cells for 3D drug sensitivity and resistance testing. This finding offers promising prospects for automating this process in drug testing.
Academic scientists will receive funding to establish a pleiotropic brain-penetrant small-molecule to impede glioblastoma and develop an epigenetic therapy for Prader-Willi syndrome. The TRxA program aims to bridge the drug development 'valley of death' and advance novel therapeutics from lab to clinical trials.
Researchers discovered crucial differences in venoms across the lifecycle of cone snails, using a new laboratory aquarium system to study juvenile stages. The findings reveal unique adaptations for hunting and venom composition, offering potential new drugs for pain medication and disease treatment.
Researchers have developed a new AI model that can quickly screen large libraries of potential drug compounds against target proteins. The ConPLex model uses language analysis to match potential drugs with proteins without needing to calculate molecular structures, enabling fast screening of over 100 million compounds per day.
Researchers developed a mass spectrometry method to analyze molecular glues and assess their relative strengths. The technique enables the elucidation of mechanisms through which these molecules stabilize protein interactions.
Researchers updated their protein localization prediction model, MULocDeep, to provide more targeted predictions for biological discoveries. The tool helps researchers design more effective experiments and advance scientific discoveries related to drug development and treating diseases like epilepsy.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers at Ohio State University developed an AI framework called G2 Retro to automatically generate chemical reactions for molecules. The framework was shown to cover a vast range of possible reactions and accurately predict the best synthesis routes, offering more efficient drug design options.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
Researchers found that T cells can self-activate by puckering their cell membrane, boosting function and slowing tumor growth in a mouse model. This discovery could inspire new anti-tumor therapeutics and provide insights into treating autoimmune diseases.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
Researchers from Integrated Biosciences developed an AI platform to discover novel senolytic compounds, a class of molecules targeting age-related processes. The platform identified three highly selective and potent compounds with favorable medicinal chemistry properties.
Three high school students co-authored a paper using AI engine PandaOmics to discover new therapeutic targets for glioblastoma multiforme, a common and aggressive malignant brain tumor. The study identified three genes strongly correlated with both aging and glioblastoma as potential therapeutic targets.
Scripps Research scientists develop a new strategy to identify small molecules that can alter protein function, offering a promising path for discovering targeted cancer drugs. By comparing how mirror image versions of small molecules impact clusters of proteins, they identified potential new drug targets such as MY-1B and EV-96.
Researchers developed a high-throughput assay to analyze CAR-T cells' effects on 3D tumor spheroid models using plate-based image cytometry. This study demonstrates the potential benefits of this method for assessing potency, specificity, and location of CAR-T cells in relation to spheroids.
Researchers at UBC and the University of Michigan have discovered a new compound, MPI 8, that prevents blood clots without increasing bleeding risk. This breakthrough could lead to improved treatment options for patients affected by blood clots.
Researchers at Hokkaido University have developed a simplified Birch reduction method that avoids liquid ammonia and can be carried out in ambient air, making it faster and more eco-friendly. The mechanochemical approach uses a ball mill to break through the surface layer on lithium metal, enabling the Birch reduction to proceed.
Human macrophages use Siglec-14 receptors to recognize and engulf carbon nanotubes, leading to inflammation. The discovery could pave the way for developing safer carbon nanotubes and therapies to prevent inflammatory diseases.
Researchers have identified a common amino acid, glycine, as a potential trigger for major depression, anxiety, and other mood disorders. The discovery improves understanding of the biological causes of major depression and could accelerate efforts to develop new medications.
Scientists have found that glycine, an amino acid, can deliver a 'slow-down' signal to the brain, influencing major depression and anxiety in some people. The discovery improves understanding of the biological causes of major depression and could lead to new, faster-acting medications.
The March special issue of SLAS Discovery introduces protocol articles highlighting detailed scientific methods and procedures in drug discovery. The issue covers topics such as 3D imaging, cancer treatments, and high-throughput screening, emphasizing transparency and rigor in research methodology.
A small molecule discovered by University of Houston researchers could potentially shorten the course of SARS-CoV-2 infection, offering a new alternative treatment option for COVID-19. The compound, CD04872SC, has shown promise in neutralizing the virus and its variants Delta and Omicron.
The Lp(a) Discovery Project will develop clinical standards for optimal patient care through a new screening measure and quality improvement interventions. The three-year project aims to fill knowledge gaps around Lp(a) and encourage better treatments to reduce cardiovascular risk.
Researchers from China have identified inosine as a potential broad-spectrum anti-inflammatory agent that improves survival in mice infected with SARS-CoV-2. The study also highlights TBK1 as a promising target for inhibiting cytokine storms and mitigating acute inflammatory lung injury.
A team of researchers at Kyoto University has established a method to identify individual inbred medaka killifish by analyzing the characteristic patterns of dark spots on their heads. This identification method may contribute to biometrics for medical and drug discovery research.
A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The therapy targets a DNA repair protein and shows promise in clinical trials.
A new drug called CADD522 blocks a gene associated with driving bone cancer's spread, increasing survival rates by 50% in mice implanted with human bone cancer. The breakthrough treatment shows promise in all main bone cancer subtypes and has the potential to save lives and reduce disability.
A recent study found that public investment in critical research contributed significantly to the development of mRNA COVID-19 vaccines. The US government invested at least $337 million in research over 35 years, including basic science and vaccine development.
Scientists at St. Jude Children's Research Hospital demonstrate a framework to develop solutions to evade detoxification networks in drug development, potentially reducing side effects. By altering the structure of a small molecule, they found a way to stretch out binding regions, making it energetically unfavorable for drugs to bind a...
Researchers developed a new prototype treatment using a human antibody that neutralizes neurotoxins from African and Asian elapid snakes, with potential for broader cross-reactivity. The treatment showed promising results in preventing death from venom envenoming in mice.
The ESMO Targeted Anticancer Therapies Congress 2023 features presentations on drug discovery and development for various targets, precision medicine, and early clinical trial methodology. Keynote lectures highlight novel insights in mutational signatures and epigenetic therapies.
The SLAS Discovery Editor's Top 10 for 2022 showcases articles on COVID-19 drug discovery, 3D organoid systems, and treatments for diseases such as autism spectrum disorder and obesity. These top articles demonstrate the impact of high-throughput screening approaches and innovative technologies in advancing scientific collaboration.
The 6th Annual Meeting of the Labroots Drug Discovery & Development Virtual Event Series will bring together specialists to discuss ongoing research in drug discovery and development. Keynote speaker Professor Kevin Pfleger will present novel pharmacology findings, while attendees can earn free CE credits.
A new protein degrader, AK-2292, shows promise against STAT5, a key player in leukemia and other cancers. By targeting the protein's degradation, researchers have overcome previous challenges in designing small molecule inhibitors.
A new experimental contraceptive drug has been developed by Weill Cornell Medicine investigators, demonstrating the possibility of an on-demand male contraceptive. The study found that a single dose of the sAC inhibitor TDI-11861 temporarily stops sperm movement and prevents pregnancies in preclinical models.
Researchers from Tokyo University of Science discovered β-damascone, a natural aroma compound found in rose fragrance, modulates dendritic cell functions and reduces inflammatory cytokine production. The study showed β-damascone inhibits antigen-dependent activation and Th1 cell development, as well as ear inflammation in mice models.
Researchers utilized the Chemistry42 platform to generate novel molecular structures and identified a hit molecule for CDK20, a promising target for hepatocellular carcinoma. The platform's customizable reward function and generative models enabled efficient design and optimization of molecules.
A new analysis of NETosis from Dompé farmaceutici puts a spotlight on neutrophils in carcinogenesis. Neutrophils' behavior is modulated by extracellular vesicles and interleukin-8, leading to tumor progression and drug resistance. Targeting IL-8 and EVs may lead to novel drugs to regulate neutrophil biology.
Eleni Tomazou's project aims to create in vitro and in vivo models of pediatric sarcomas to accelerate drug discovery and precision medicine. Her work could lead to a significant impact on the treatment of these deadly cancers.
Researchers have identified a new class of potent antimalarial compounds that target the parasite's sexual phase, preventing it from infecting mosquitoes and subsequently humans. The compounds inhibit the parasitic protein Pfs16, forming the strongest bond with the drug.
UC San Diego scientists developed an AI-based strategy for discovering high-affinity antibody drugs, identifying a new antibody that binds 17 times tighter than an existing one. The approach accelerates the discovery process, reducing failure rates and enabling faster development of novel cancer and COVID-19 treatments.
Researchers uncover how changing trends in interorganizational deals in the pharmaceutical industry are improving drug discovery and R&D productivity. The study found that M&A-related deals drive revenue growth for large pharmaceutical companies, and academia-owned spinouts of advanced technology are increasing.